demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID-19 mild to moderate
anticoagulant
anticoagulant, curative dose ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose RAPID ...

23 studies excluded by filtering options 0

5071 Tang, 2020 1133not a RCThigh risk of bias
5355 Paranjpe, 2020 1134not a RCThigh risk of bias
5404 Tremblay, 2020 1130not a RCTrisk of bias not avaialble
5441 Ayerbe, 2020 1130not a RCTrisk of bias not avaialble
5679 ATTACC (Houston), 0 010selection pending
5777 Bousquet, 2020 1130not a RCTrisk of bias not avaialble
5777 Bousquet, 2020 1130not a RCTrisk of bias not avaialble
5845 ACTIV-4a (heparin), 0 010selection pending
5889 REMAP-CAP Anticoagulation, 0 010selection pending
5891 HEP-COVID, 2021 010selection pending
5895 X-COVID-19, 2021 010selection pending
6283 Lynn, 2020 0130selection pending
6364 Denas, 2020 000selection pending
6393 Rossi, 2020 1130not a RCTrisk of bias not avaialble
6396 Russo, 2020 1130not a RCTrisk of bias not avaialble
6404 Trinh, 2020 1130not a RCTrisk of bias not avaialble
6405 Li [retracted], 2020 200excludedrisk of bias not avaialble
6406 Gonzalez-Porras, 2020 1130not a RCTrisk of bias not avaialble
6406 Gonzalez-Porras, 2020 1130not a RCTrisk of bias not avaialble
6439 Gonzalez-Ochoa, 2020 000selection pending
6448 Ménager, 2020 000selection pending
9169 MICHELLE, 2021 010selection pending
10523 FREEDOM COVID, 2023 010selection pending